uniQure plans to submit UK application for Huntington's disease therapy, shares up

uniQure

30/04/2026 13:06

** U.S.-listed shares of Dutch firm uniQure UQ1.F, QURE.O rise 10% to $18.41 premarket

** Co says it plans to submit a marketing authorization application in the UK for its experimental gene therapy AMT-130 for Huntington's disease in Q3

** Adds meeting with the FDA still expected in Q2

** "We think the ability to file in the UK is an incremental positive for QURE after a long and difficult road with the FDA in the US," Barclays says

** FDA and QURE have been in a public back and forth over the gene therapy

** Huntington's disease is a rare condition that affects motor function

** Up to last close, stock down 30% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))